GlobeNewswire

Creating Long-Term Value for Our Members

Dela

HOOPP Tops $77.8 Billion In Net Assets with A 10.88% Rate Of Return

 

TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) announced today that its Funded Status at the end of 2017 was 122%, unchanged from the prior year.

The Fund's net assets reached $77.8 billion, up from $70.4 billion in 2016, following a rate of return on investments of 10.88% in 2017. After several years of stellar investment performance resulting in funding surpluses, the Board of Trustees approved enhancements to members' benefits during the year and committed to maintain contribution rates made by HOOPP members and their employers at the same level until at least 2019. These rates have remained unchanged since 2004.

Investment income for the year was $7.6 billion compared to $6.6 billion in 2016, and the Fund's 10.88% investment return exceeded its portfolio benchmark by 2.99% or $2.0 billion. The Fund's 10-year annualized return is 9.55% and its 20-year annualized return is 9.01%.

"Our investment return for 2017 was 10.88%. While we had strong returns pretty much across all asset classes, our public and private equities, fixed income and real estate all provided significant contributions to our investment income," says HOOPP President and CEO Jim Keohane.

"HOOPP exists to pay pensions for members. We invest with that objective in mind to ensure that we can meet our pension obligation regardless of the economic backdrop. We also continue to reinvest in our personnel and our systems in order to maintain the sustainability of the Fund and support growth going forward," added Keohane.

HOOPP's pioneering investment model of liability driven investing has proven to be a foundation of the organization's ability to provide adequate and predictable retirement security to its members and being able to deliver on the pension promise. This risk management approach to investing ensures that HOOPP can effectively adapt to changes in the market to ensure stability and avoid negative impact on the Fund. The success of HOOPP's funding and investment strategy can be attributed to the organization's focus on long-term vision and approaches.

For more information about HOOPP's financial results please view the 2017 Annual Report, available on hoopp.com.

2017 Return Highlights

HOOPP's liability driven investing approach utilizes two investment portfolios:  a liability hedge portfolio that seeks to mitigate certain risks associated with our pension obligations, and a return seeking portfolio designed to earn incremental returns to help to keep contribution rates stable and affordable.

In 2017, the liability hedge portfolio provided approximately 48% of our investment income. Nominal bonds returned 10.5% while real return bond returns were essentially flat. The real estate portfolio was a significant contributor during the year, with an 11.9% currency hedged return.

Within the return seeking portfolio, which provided 52% of the Fund's income, public equities were the largest contributor to investment income, returning 14.8%, while private equity investments returned 19.6% on a currency hedged basis.

About the Healthcare of Ontario Pension Plan

Created in 1960, HOOPP is a multi-employer contributory defined benefit plan for Ontario's hospital and community-based healthcare sector with 548 participating employers. HOOPP's membership includes nurses, medical technicians, food services staff and housekeeping staff, and many other people who work hard to provide valued Ontario healthcare services. In total, HOOPP has more than 339,000 active, deferred and retired members.

As a defined benefit plan, HOOPP provides eligible members with a retirement income based on a formula that takes into account a member's earnings history and length of service in the Plan. HOOPP is governed by a Board of Trustees with representation from the Ontario Hospital Association (OHA) and four unions: the Ontario Nurses' Association (ONA), the Canadian Union of Public Employees (CUPE), the Ontario Public Service Employees' Union (OPSEU), and the Service Employees International Union (SEIU). The unique governance model provides representation from both management and workers in support of the long-term interests of the Plan.  

For further information or to arrange interviews, please contact:
Judy Mann
Senior Director, Public Relations, Plan and Corporate Communications
T) 416-369-8033   C) 416-270-3619

Twitter
LinkedIn  
|  #HOOPPresults2017

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a201e6ce-11be-4193-bc92-13b6351d2f26




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CAD - Healthcare of Ontario Pension Plan via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum